Dabur Pharma gets US FDA approval for cancer drug
By Our Corporate Bureau | 07 Dec 2006
Mumbai: Dabur Pharma Ltd has received approval from the US Food and Drug Administration (USFDA) for its oncology drug 'Paclitaxel' injections, the regulatory agency said in a release on its website.
Paclitaxel is the generic equivalent of Bristol-Myers Squibb Company's Taxol, used in treating ovarian and breast cancer.
Dabur Pharma's wholly owned arm in the UK, Dabur Oncology, was granted ANDA approval for its Paclitaxel molecule.
Dabur Pharma Ltd (DPL), earlier part of Dabur Industries (DIL), announced a virtual demerger from DIL in July 2002. The demerger process was completed in December 2003. DPL is a specialty pharmaceuticals company with a focus on oncology.
Dabur Pharma has reported a 45.97 per cent rise in its profit after tax and exceptional items, at Rs 6.96 crore for the quarter ended September 30, 2006, as compared to Rs 4.77 crore for the quarter ended September 30, 2005.
Total income increased by 33.02 per cent to Rs 94.29 crore for the quarter ended September 30, 2006 from Rs 70.88 crore for the quarter ended September 30, 2005.
Dabur Pharma manufactures and markets oral and injectable dosage forms and active pharmaceutical ingredients and intermediates. The group also works in the field of cancer research and anticancer products. It markets products in the cardiovascular, antibacterial, antidiabetic and digestive segments. Dabur Pharma markets its products in India, Nepal, Bangladesh, Sri Lanka, Thailand, the Philippines, Malaysia, Vietnam, Myanmar, Jordan, Cyprus, Russia, Ukraine, Belarus, Georgia, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Colombia, Venezuela, Peru, Costa Rica, Mexico, Barbados and Jamaica.
